Shi, Zhen

Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation

Sacher, A., LoRusso, P., Patel, M. R., Miller, W. H., Garralda, E., Forster, M. D., Santoro, A., Falcon, A., Kim, T. W., Paz-Ares, L., et al. (2023) · New England Journal of Medicine

Lung Cancer Treatments and MutationsProtein Kinase Regulation and GTPase Signaling

Cited by 328

Translation control of the immune checkpoint in cancer and its therapeutic targeting

Xu, Y., Poggio, M., Jin, H. Y., Shi, Z., Forester, C. M., Wang, Y., Stumpf, C. R., Xue, L., Devericks, E., So, L., et al. (2019) · Nature Medicine

Cancer Immunotherapy and BiomarkersRNA and protein synthesis mechanisms

Cited by 261

Translating the genome in time and space: Specialized ribosomes, RNA regulons, and RNA-binding proteins

Shi, Z., & Barna, M. (2015) · Annual Review of Cell and Developmental Biology

RNA and protein synthesis mechanismsRNA Research and Splicing

Cited by 205

Comprehensive pan-cancer genomic landscape of KRAS altered cancers and real-world outcomes in solid tumors

Lee, J. K., Sivakumar, S., Schrock, A. B., Madison, R., Fabrizio, D., Gjoerup, O., Ross, J. S., Frampton, G. M., Napalkov, P., Montesion, M., et al. (2022) · npj Precision Oncology

Cancer Genomics and DiagnosticsProtein Kinase Regulation and GTPase Signaling

Cited by 187

Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial

Desai, J., Alonso, G., Kim, S. H., Cervantes, A., Karasic, T., Medina, L., Shacham-Shmueli, E., Cosman, R., Falcon, A., Gort, E., et al. (2024) · Nature Medicine

Colorectal Cancer Treatments and StudiesLung Cancer Treatments and Mutations

Cited by 144

Overall survival in patients with advanced non-small cell lung cancer with KRAS G12C mutation with or without STK11 and/or KEAP1 mutations in a real-world setting

Julian, C., Pal, N., Gershon, A., Evangelista, M., Purkey, H., Lambert, P., Shi, Z., & Zhang, Q. (2023) · BMC Cancer

Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment

Cited by 31

A saturation mutagenesis screen uncovers resistant and sensitizing secondary KRAS mutations to clinical KRAS G12C inhibitors

Feng, S., Callow, M. G., Fortin, J.-P., Khan, Z., Bray, D., Costa, M., Shi, Z., Wang, W., & Evangelista, M. (2022) · Proceedings of the National Academy of Sciences

Lung Cancer Treatments and MutationsProtein Kinase Regulation and GTPase Signaling

Cited by 27

Circulating Tumor DNA Dynamics Reveal KRAS G12C Mutation Heterogeneity and Response to Treatment with the KRAS G12C Inhibitor Divarasib in Solid Tumors

Choi, Y., Dharia, N. V., Jun, T., Chang, J., Royer-Joo, S., Yau, K. K., Assaf, Z. J., Aimi, J., Sivakumar, S., Montesion, M., et al. (2024) · Clinical Cancer Research

Cancer Genomics and DiagnosticsLung Cancer Treatments and Mutations

Cited by 23

Assessment of KRAS G12C Target Engagement by a Covalent Inhibitor in Tumor Biopsies Using an Ultra-Sensitive Immunoaffinity 2D-LC–MS/MS Approach

Meng, L., Chan, E. W., Ng, C., Aimi, J., Tran, J. C., Oh, A. J., Merchant, M., Purkey, H. E., Heffron, T. P., Kaur, S., et al. (2022) · Analytical Chemistry

Protein Kinase Regulation and GTPase SignalingLung Cancer Treatments and Mutations

Cited by 15